ICMJE DISCLOSURE FORM					
Date:	ate: 3/22/2023				
Your Name:	Our Name: Alejandro Bimbo Diaz				
Manuscript Title:	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region	_			
Manuscript Number (if k	known): Click or tap here to enter text.	_			
content of your manuscr affected by the content of indicate a bias. If you are The author's relationship epidemiology of hyperte that medication is not m	rency, we ask you to disclose all relationships/activities/interests listed below that are related to the ript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be of the manuscript. Disclosure represents a commitment to transparency and does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. Disclosure represents a commitment to transparency and does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. Disclosure represents a commitment to transparency and does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. Disclosure represents a commitment to transparency and does not necessarily in does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. Disclosure represents a commitment to transparency and does not necessarily in does				
	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)				

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments made to you or to your institution)		
		Time frame: Since the initial planning of	of the work	
1	All support for the present	None		
	manuscript (e.g., funding, provision	In Vivo Communications Pte Ltd	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
	of study materials, medical writing,		Click the tab key to add additional rows.	
	article processing charges, etc.) No time limit for			
	this item.			
		Time frame: past 36 months	S	
2	Grants or contracts from	[⊠] None		
	any entity (if not indicated in item			
	#1 above).			
3	Royalties or licenses	⊠ None		
	licerises			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Menarini Philippines Pfizer	Honorarium for advisory Board Speaker honorarium
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date: 3/22/2023					
Your Name:			Jeremy Chow		
Manuscript Title:			Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region		
Mar	nuscript Number (if l	known):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the man			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epic	•	ension, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			ithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present		one		
	manuscript (e.g., funding, provision	In Vivo	Communications Pte Ltd	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
	of study materials,				
	medical writing, article processing			Click the tab key to add additional rows.	
	charges, etc.) No time limit for this item.				
			Time frame: past 36 month	S	
2	Grants or contracts from		one		
	any entity (if not indicated in item				
	#1 above).				
3	Royalties or	⊠ No	one		
3	licenses		Jile		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]		t to the following statement to indicate your agreement answered every question and have not altered the wo	

Date:		-	3/22/2023		
Your Name:		-	Fan Kee Hoo		
Manuscript Title:		_	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region		
Ma	nuscript Number (if kı	nown):	Click or tap here to enter text.		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			ot-for-profit third parties whose interests may be nt to transparency and does not necessarily //interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if		
		Name all	entities with whom you have this	Specifications/Comments (e.g., if payments were	
		relations	hip or indicate none (add rows as needed)	made to you or to your institution)	
		relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning	made to you or to your institution)	
1	All support for the present	[□] No	Time frame: Since the initial planning	made to you or to your institution) of the work	
1	All support for the	[□] No	Time frame: Since the initial planning	made to you or to your institution) of the work Editorial support for manuscript writing funded	
1	All support for the present manuscript (e.g., funding, provision of study materials,	[□] No	Time frame: Since the initial planning	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	All support for the present manuscript (e.g., funding, provision	[□] No	Time frame: Since the initial planning	made to you or to your institution) of the work Editorial support for manuscript writing funded	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	[□] No	Time frame: Since the initial planning	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	□ No	Time frame: Since the initial planning	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]		t to the following statement to indicate your agreement answered every question and have not altered the wo	

Date:			3/22/2023		
Your Name:		_[Kok Wei Koh		
Manuscript Title:		L.	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region		
Ma	nuscript Number (if k	nown):	Click or tap here to enter text.		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt			ed" means any relation with for-profit or no		
-	demiology of hyperter t medication is not me	-	-	acturers of antihypertensive medication, even if	
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
			entities with whom you have this ip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
			Branch Street St	of the work	
1	All support for the present	[□] Non	ne		
1	present manuscript (e.g., funding, provision			Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	present manuscript (e.g., funding, provision of study materials,		ne	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	present manuscript (e.g., funding, provision		ne	Editorial support for manuscript writing funded	
1	present manuscript (e.g., funding, provision of study materials, medical writing,		ne	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		ne	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from		ommunications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	In Vivo Co	ommunications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	In Vivo Co	ommunications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	In Vivo Co	ommunications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	In Vivo Co	ommunications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Menarini Boehringer Bayer	Honoraria Honoraria Honoraria
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

	ICMJE DISCLOSURE FORM				
Dat	Date: 3/22/2023				
Υοι	Our Name: Gary Lee Chin Keong				
Ma	nuscript Title:	Fitle: Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region			
Ma	nuscript Number (if k	nown): Click or tap here to enter text.			
cor affe ind The epi tha	ected by the content of icate a bias. If you are a author's relationship demiology of hyperter t medication is not me	rency, we ask you to disclose all relationships/activities of the manuscript. Disclosure represents a commitme in doubt about whether to list a relationship/activity s/activities/interests should be defined broadly. For ension, you should declare all relationships with manufactioned in the manuscript. all support for the work reported in this manuscript we past 36 months.	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily //interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if		
	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initial planning	of the work		
1	All support for the	None			

		relationship or indicate none (add rows as needed)	made to you or to your institution)
I		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None In Vivo Communications Pte Ltd Time frame: past 36 month	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.
	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			3/22/2023		
Your Name:			Wee Siong Teo		
Manuscript Title:			Early experiences with edoxaban for stroke Asia region	prevention in atrial fibrillation in the Southeast	
Ma	nuscript Number (if kı	nown):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the ma		ipt. "Rela of the mar			
epi		nsion, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
In item #1 below, report all suppo frame for disclosure is the past 36				ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			-	made to you or to your institution)	
1	All support for the	relations	hip or indicate none (add rows as needed)	made to you or to your institution)	
1	All support for the present manuscript (e.g., funding, provision	relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning	made to you or to your institution)	
1	All support for the present manuscript (e.g.,	relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning one	made to you or to your institution) of the work Editorial support for manuscript writing funded	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning one	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning one	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	relations	hip or indicate none (add rows as needed) Time frame: Since the initial planning one	made to you or to your institution) of the work Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.	

1 12/13/2021 ICMJE Disclosure Form

#1 above).

Royalties or

licenses

⊠ None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Menarini Boehringer Ingelheim Bayer Pfizer	Advisory Board honorarium Advisory Board honorarium Advisory Board honorarium Advisory Board honorarium
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/22/2023
Your Name:	Narayanaswamy Venketasubramanian
Manuscript Title:	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
Manuscript Number (if known):	Click or tap here to enter text.
In the interest of transparency, w	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	In Vivo Communications Pte Ltd Time frame: past 36 months	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	■ None	
3	Royalties or licenses	None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:		3/22/2023	3/22/2023		
Your Name:		Chun-Chieh Wang	Chun-Chieh Wang		
Manuscript Title:		Early experiences with edoxaba Asia region	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region		
Mai	nuscript Number (if kno	wn): Click or tap here to enter text.			
con affe	tent of your manuscript ected by the content of t	. "Related" means any relation with for he manuscript. Disclosure represents a	hips/activities/interests listed below that are related to the r-profit or not-for-profit third parties whose interests may lacommitment to transparency and does not necessarily ship/activity/interest, it is preferable that you do so.		
epic	demiology of hypertensi		roadly. For example, if your manuscript pertains to the with manufacturers of antihypertensive medication, even	if	
	em #1 below, report all ne for disclosure is the p		nanuscript without time limit. For all other items, the time		
		ame all entities with whom you have th lationship or indicate none (add rows a		were	
		_	as needed) made to you or to your institution)	were	
1	All support for the	lationship or indicate none (add rows a	as needed) made to you or to your institution)	were	
1	All support for the present manuscript (e.g., funding, provision	lationship or indicate none (add rows a	as needed) made to you or to your institution)		
1	All support for the present manuscript (e.g.,	lationship or indicate none (add rows a Time frame: Since the init None	as needed) made to you or to your institution) tial planning of the work Editorial support for manuscript writing funde		
1	All support for the present manuscript (e.g., funding, provision of study materials,	lationship or indicate none (add rows a Time frame: Since the init None	as needed) made to you or to your institution) tial planning of the work Editorial support for manuscript writing funde by A. Menarini Asia-Pacific Pte. Ltd.		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	lationship or indicate none (add rows a Time frame: Since the init None	Editorial support for manuscript writing funde by A. Menarini Asia-Pacific Pte. Ltd. Click the tab key to add additional rows.		

Royalties or

licenses

⊠ None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None □ Daiichi-Sankyo □ Boehringer Ingelheim □ Bayer □ Daiichi-Sankyo	Speaker honorarium Speaker honorarium Speaker honorarium
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	Daiichi-Sankyo	Steering Committee member of the Global ETNA-AF program
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Dat	e:	3/22/2023			
Your Name:		Radhika Mehta	Radhika Mehta		
Mai	nuscript Title:	Early experiences with edoxaban for stro Asia region	Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region		
Ma	nuscript Number (if k	nown): Click or tap here to enter text.			
con affe indi	tent of your manuscri ected by the content o cate a bias. If you are	rency, we ask you to disclose all relationships/activ pt. "Related" means any relation with for-profit or f the manuscript. Disclosure represents a commitr in doubt about whether to list a relationship/activ	not-for-profit third parties whose interests may be nent to transparency and does not necessarily ity/interest, it is preferable that you do so.		
-		nsion, you should declare all relationships with marentioned in the manuscript.	ufacturers of antihypertensive medication, even if		
In it		all support for the work reported in this manuscrip	without time limit. For all other items, the time		
		Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planni	ng of the work		
1	All support for the present manuscript (e.g.,	□ None	Editorial current for manuscript writing funded		
	funding, provision	In Vivo Communications Pte Ltd	Editorial support for manuscript writing funded by A. Menarini Asia-Pacific Pte. Ltd.		
	of study materials, medical writing,		Click the tab key to add additional rows.		
	article processing charges, etc.) No time limit for this item.				
		Time frame: past 36 mor	ths		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			

licenses

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	A. Menarini Asia-Pacific Pte. Ltd	Employee of A. Menarini Asia-Pacific Pte. Ltd
Plea	Please place an "X" next to the following statement to indicate your agreement:		